Home › Follicular Lymphoma › New York › New York City
Pag-aaral pangklinika para sa Follicular Lymphoma sa New York City, NY
24 pag-aaral para sa Follicular Lymphoma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng New York City (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
- Columbia University Medical Center, New York
- Weill Cornell Medical College Newyork Presbyterian Hospital, New York
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Nagre-recruitPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Nagre-recruitPhase 1/2
- Research Site, New York
- Research Site, New York
Epco, Zanu, Ritux for R/R FL or MZL
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
- New York University (NYU) Clinical Cancer Center, New York
- Weill Cornell Medicine, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Nagre-recruitPhase 1/2
- New York University Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Nagre-recruitPhase 1
- Columbia University, New York
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Nagre-recruitPhase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Nagre-recruitPhase 2
- Research Site, New York
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Nagre-recruitPhase 3
- Mount Sinai Medical Center, New York
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Nagre-recruitPhase 3
- Icahn School of Medicine at Mt Sinai, New York
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Nagre-recruitPhase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nagre-recruitPhase 3
- NYU Langone Health, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University Medical Center, New York
- at 1 pa
A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
- NYU Langone, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Nagre-recruitPhase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
Nagre-recruit
- New York State Psychiatric Institute (NYSPI) / Substance Treatment and Research Service (STARS), New York
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Nagre-recruitPhase 2
- Memorial Sloan Kettering Cancer Center, New York
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
- Memorial Sloan Kettering Cancer Center - Bergen, New York
Chronic CED of TPT for Recurrent Malignant Glioma
Nagre-recruitPhase 1
- Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Nagre-recruitPhase 2
- Icahn School of Medicine at Mount Sinai Hospital, New York
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Nagre-recruitPhase 2
- Icahn School of Medicine at Mount Sinai, New York
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Nagre-recruitPhase 3
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of SGR-1505 in Mature B-Cell Neoplasms
Nagre-recruitPhase 1
- Weill Cornell, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, New York
Pag-aaral para sa Follicular Lymphoma sa ibang lungsod
- Milwaukee, WI19 pag-aaral
- Nashville, TN18 pag-aaral
- Houston, TX18 pag-aaral
- Boston, MA17 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Seattle, WA15 pag-aaral
- Durham, NC15 pag-aaral
- Salt Lake City, UT13 pag-aaral
- Columbus, OH13 pag-aaral
- Chicago, IL12 pag-aaral
- San Antonio, TX12 pag-aaral
- Philadelphia, PA12 pag-aaral
Iba pang pag-aaral sa New York City
- Kanser sa Suso136 pag-aaral
- Non-Small Cell Lung Cancer121 pag-aaral
- Kanser (lahat ng uri)109 pag-aaral
- Kanser sa Prostate103 pag-aaral
- Metastatic Cancer93 pag-aaral
- Colorectal Cancer78 pag-aaral
- Kanser sa Ovary69 pag-aaral
- Kanser sa Baga60 pag-aaral
- Multiple Myeloma60 pag-aaral
- Kanser sa Pancreas60 pag-aaral
- Kanser ng Endometrium52 pag-aaral
- Acute Myeloid Leukemia51 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.